40 episodes listed below
Author context for ophthalmology evidence.
JAMA Ophthalmology Author Interviews brings article authors into careful, question-led conversations about eye disease research and clinical practice. The tone is formal but practical, moving from study design and patient populations to what the findings may mean in clinical care or surgery.
PRESS PLAY
JAMA Ophthalmology Author Interviews is a journal-adjacent interview series for listeners who follow clinical ophthalmology research closely. It is precise, orderly, and evidence-first. Episodes are built around published studies, usually with an author explaining the clinical problem, the study design, the main findings, and the questions left unresolved. Neil Bressler regularly provides the frame as Editor-in-Chief of JAMA Ophthalmology, then pushes for practical interpretation. The conversations do not treat research findings as simple takeaways. They ask what counts as meaningful improvement, what a comparator arm really showed, and where caution is needed before changing practice. Recent episodes move across retina, cornea, glaucoma, pediatrics, and neuro-ophthalmology. One discussion considers mTOR inhibition as a possible target for preventing proliferative vitreoretinopathy after retinal detachment repair. Another walks through a randomized clinical trial testing topical corticosteroids and corneal cross-linking for bacterial keratitis, including the disappointment of no clear visual acuity advantage among treatment arms. The PAGODA trial episode examines continuous ranibizumab through a port delivery system compared with monthly ranibizumab for diabetic macular edema, including the tradeoff of transient postoperative visual decline. A glaucoma episode weighs selective laser trabeculoplasty against primary eyedrops through a post-hoc look at LiGHT trial data. The show also makes room for workforce and training questions, including gender differences in surgical case volume among ophthalmology resident graduates. Its register is professional and methodical. Listeners hear about propensity matching, exclusion criteria, surgical adverse events, database limits, and the difference between association and causation. That makes the series best suited to clinicians, residents, fellows, researchers, and medically fluent listeners who want the study behind the abstract. It is less useful for someone seeking broad eye-health advice or simplified patient education. The value is in the author-level context: why the study was done, how the investigators measured outcomes, and what the evidence can responsibly support. Even when the findings are negative or preliminary, the conversations clarify the clinical stakes. The result is compact continuing-education style listening with the cadence of peer review.
Made for: Built for ophthalmologists, vision researchers, residents, fellows, and medically fluent listeners who want study design, outcomes, and clinical relevance explained by the authors. It assumes comfort with specialist terminology.
What sets it apart: The series stays unusually close to the published evidence, pairing article authors with pointed editorial questioning about methods, limits, and practice implications. It values restraint as much as novelty.
Interviews with authors of articles from JAMA Ophthalmology. JAMA Ophthalmology, published continuously since 1869, is an international, peer-reviewed ophthalmology and visual science journal. Covering research, science, & clinical practice in ophthalmology and vision science.
An eye implant sounds elegant until Neil Bressler asks about vision after surgery.
Press play if you want
Short reviews from the PlayNext desk, based on the episodes we processed.
A measured, accessible look at mTOR inhibition as a possible target for PVR after retinal detachment repair.
Preventing proliferative vitreoretinopathy means facing a major reason retinal detachment repair can fail, and this PlayNext episode keeps that problem concrete. Dr.
A clear, clinically focused discussion of IIH, GLP-1 receptor agonists, and the treatment choices around them.
Idiopathic intracranial hypertension gets a clear clinical frame here, with attention to headaches, tinnitus, visual impairment, and the urgency of accurate diagnosis and treatment when vision is at risk. Dr. Cynthia Armand leads Dr.
A clear-eyed look at whether continuous ranibizumab delivery can ease the monthly burden in diabetic macular edema.
PAGODA centers on a practical question in diabetic macular edema care: whether continuous ranibizumab through a port delivery system can stand up against monthly ranibizumab.
Oncology evidence translated into clinical decisions.
Critical care evidence, carefully talked through.
Clinical research, reduced to its practical signal.
Dr. Rahimi says mTOR inhibitors were linked to a 40% to 43% lower redetachment risk within one year.
Dr.
Neil Bressler and Dr.
Bradley Katz recommends slower glucose reduction with semaglutide and tirzepatide while further optic-neuropathy surveillance continues.
An OHSU prototype captured images in all 83 enrolled infants, and each full-field ultra-wide-field OCT scan took about one second.
Curcumin supplement users had nearly one-tenth the geographic atrophy risk in a retrospective analysis, a magnitude Neil Bressler questions for possible confounding.
An interview with Dr.
JAMA Ophthalmology Author Interviews features Harold interviewing Kirsten Bibbins-Domingo about her appointment as editor-in-chief of JAMA and the JAMA Network.